MÓCIKOVÁ, Heidi, Robert PYTLIK, Pavla STEPANKOVA, Jozef MICHALKA, Jana MARKOVA, Jan KOREN, Lucie BURESOVA, Ludek RAIDA a Zdeněk KRÁL. Can Rituximab Improve the Outcome of Patients with Nodular Lymphocyte-Predominant Hodgkin's Lymphoma? Acta Haematologica. Basel: Karger, roč. 134, č. 3, s. 187-192. ISSN 0001-5792. doi:10.1159/000381327. 2015. |
Další formáty:
BibTeX
LaTeX
RIS
@article{1335235, author = {Móciková, Heidi and Pytlik, Robert and Stepankova, Pavla and Michalka, Jozef and Markova, Jana and Koren, Jan and Buresova, Lucie and Raida, Ludek and Král, Zdeněk}, article_location = {Basel}, article_number = {3}, doi = {http://dx.doi.org/10.1159/000381327}, keywords = {Chemotherapy; Hodgkin's lymphoma; Nodular lymphocyte-predominant Hodgkin's lymphoma; Rituximab}, language = {eng}, issn = {0001-5792}, journal = {Acta Haematologica}, title = {Can Rituximab Improve the Outcome of Patients with Nodular Lymphocyte-Predominant Hodgkin's Lymphoma?}, volume = {134}, year = {2015} }
TY - JOUR ID - 1335235 AU - Móciková, Heidi - Pytlik, Robert - Stepankova, Pavla - Michalka, Jozef - Markova, Jana - Koren, Jan - Buresova, Lucie - Raida, Ludek - Král, Zdeněk PY - 2015 TI - Can Rituximab Improve the Outcome of Patients with Nodular Lymphocyte-Predominant Hodgkin's Lymphoma? JF - Acta Haematologica VL - 134 IS - 3 SP - 187-192 EP - 187-192 PB - Karger SN - 00015792 KW - Chemotherapy KW - Hodgkin's lymphoma KW - Nodular lymphocyte-predominant Hodgkin's lymphoma KW - Rituximab N2 - Background: Nodular lymphocyte-predominant Hodgkin's lymphoma (NLPHL) is a rare subtype of Hodgkin's lymphoma showing strong CD20 expression. The role of rituximab in treating NLPHL still needs clarification. Methods: We retrospectively reviewed the outcome of 23 patients with NLPHL treated with rituximab alone or in combination with chemotherapy and/or radiotherapy as part of their first-or second-line treatment. Results: The median follow-up of the whole group was 67 months, and all patients remained alive. Twenty-two patients achieved complete remission after rituximab-based therapy, and one of them relapsed 32 months after treatment. One patient treated with rituximab alone achieved partial remission and progressed 22 months after treatment. Conclusion: The prognosis of NLPHL is excellent. Rituximab combined with chemotherapy and/or radiotherapy appears to prevent disease progression/relapse. ER -
MÓCIKOVÁ, Heidi, Robert PYTLIK, Pavla STEPANKOVA, Jozef MICHALKA, Jana MARKOVA, Jan KOREN, Lucie BURESOVA, Ludek RAIDA a Zdeněk KRÁL. Can Rituximab Improve the Outcome of Patients with Nodular Lymphocyte-Predominant Hodgkin's Lymphoma? \textit{Acta Haematologica}. Basel: Karger, roč.~134, č.~3, s.~187-192. ISSN~0001-5792. doi:10.1159/000381327. 2015.
|